Cardioprotective effect of thymol against adrenaline-induced myocardial injury in rats

Salma A. El-Marasy, Sally A. El Awdan, Azza Hassan, Heba M.I. Abdallah

ARTICLE INFO

Keywords:
Thymol
Adrenaline
Myocardial injury
ECG examination
Oxidative stress
Inflammation
Apoptosis
Rats
Cardiology
Pathology
Pharmacology
Toxicology
Alternative medicine

ABSTRACT

Cardiovascular disease represents a vital global disease burden. This study aims to assess the possible cardioprotective effect of thymol against adrenaline-induced myocardial injury (MI) in rats. Furthermore, the effect of thymol on cardiac function biomarkers, electrocardiogram (ECG) alterations, oxidative stress, inflammation, apoptosis and histopathological changes was assessed. MI was induced by adrenaline (2 mg/kg, s.c.) injected as a single dose for 2 consecutive days (24 h apart). Normal and control groups received the vehicle for 21 consecutive days. The other 3 groups were orally administered thymol (15, 30, 60 mg/kg) for 21 consecutive days and on day 22, adrenaline was injected as a single dose for 2 consecutive days. Then ECG examination, biochemical, histopathological, immunohistochemical analyses were carried out. Thymol reversed adrenaline-induced reduction of heart rate, prolongation of RR interval and elevation of ST interval. Thymol pretreatment significantly reduced serum aspartate dehydrogenase (AST), lactate dehydrogenase (LDH), and creatine kinase (CK) levels in MI rats. Oral pretreatment with thymol increased reduced glutathione (GSH), reduced malondialdehyde (MDA), nuclear factor-kappa B (NF-κB), and interleukin-1β (IL-1β) cardiac contents in MI rats. Additionally, thymol administration significantly decreased protein expression of caspase-3, increased Bcl-2 protein expression in cardiac tissue and ameliorated histopathological changes. This study reveals that thymol exerted cardioprotective effect against adrenaline-induced MI in rats evidenced by improving cardiac function, attenuating ECG and histopathological changes which may be partly mediated through its anti-oxidant, anti-inflammatory and anti-apoptotic effect.

1. Introduction

Cardiovascular disease (CVD) is a series of disorders affecting the heart and blood vessels, including peripheral arterial disease, coronary heart disease (CHD) and congestive heart failure (CHF) (Capo et al., 2018). World health organization (WHO) estimates that by 2020, CVD will be the primary cause of death worldwide (Bei et al., 2020).

Myocardial infarction is defined as myocardial cell death due to imbalance between myocardial oxygen demand and supply (Thygesen et al., 2018; Aydin et al., 2019). It may occur secondary to atherosclerotic plaque (type 1 myocardial infarction), or variation in myocardial oxygen supply and demand without the presence of atherosclerotic plaque (type 2 myocardial infarction), or detection of ST elevation electrocardiogram (ECG) in patients (type 3 myocardial infarction). Myocardial infarction may be associated with percutaneous coronary interventions (type 4 myocardial infarction), or coronary artery bypass surgery (type 5 myocardial infarction) (Thygesen et al., 2018).

Myocardial injury (MI) is a pre-stage for the diagnosis of MI, it is also an entity in itself. Oxidative stress in MI occurs due to excessive production of reactive oxygen species (ROS) resulting in lipid peroxidation and disruption of myocardial cell membrane (Neri et al., 2015). Excessive ROS produced in MI also results in the stimulation of inflammatory and apoptotic pathways (Neri et al., 2017; Attalla et al., 2018).

Catecholamines exert inotropic and chronotropic effects on the myocardium. Excess catecholamines cause coronary vasoconstriction, resulting in an increase in myocardial oxygen demand and a reduction in myocardial blood delivery, leading to MI (Sethi and Peiris, 2020). Catecholamines-induced MI is mediated by overproduction of ROS and depletion of cardiac anti-oxidants resulting in oxidative stress and myocardial apoptosis or necrosis (Cerretani et al., 2012; Radhiga et al., 2012).

Adrenaline is a naturally occurring catecholamine and generally considered as a hormone involved in “fight or flight” mechanism (Hara et al., 2011). Adrenaline was approved as a drug and was used first in...
human cardiopulmonary resuscitation. It also possesses other therapeutic applications in the treatment of cardiac arrest, allergic reactions, glaucoma, and asthma. However, at doses exceeding physiological levels, adrenaline has been demonstrated to trigger production of ROS, reactive nitrogen species (RNS) mediated tissue damages (Díaz-Cruz et al., 2007).

Adrenaline-induced MI in rats is considered a valid experimental model which is used to investigate the cardioprotective effect of anti-oxidant agents (Mishra et al., 2016). Adrenaline was found to induce MI by causing lipid peroxidation leading to depletion of cellular antioxidants (Andreadou et al., 2009). In cardiomyocytes, adrenaline was shown to increase lipid, protein, and DNA damage with overproduction of nitrosative derivatives (Radakovic et al., 2018). Since ROS play a crucial role in the pathogenesis of MI, efforts have been directed towards the use of natural products possessing anti-oxidant activity as adjuvants with few side effects and great safety in treatment of MI (Li et al., 2012).

Thymol is a naturally occurring phenolic compound and one of the primary active constituents present in the essential oil of Thymus vulgaris (Villanueva Bermejo et al., 2015). Reports have demonstrated that thymol has shown anti-oxidant, anti-microbial (Tsai et al., 2011; Wang (Villanueva Bermejo et al., 2015). Reports have demonstrated that primary active constituents present in the essential oil of Thymus vulgaris (Amin et al. (2016) and Asadbegi et al. (2018), apart). The doses of adrenaline and thymol were selected according to previous published data of Amin et al. (2016) and Asadbegi et al. (2018), respectively.

2. Material and methods

2.1. Animals

Male albino Wistar rats weighing (120–150 g) were obtained from the animal house colony of the National Research Centre (Giza, Egypt). Animals were housed under standardized laboratory conditions (12h alternating light/dark cycle and were fed standard laboratory pellets with water ad libitum). The study protocol and procedures have been implemented in compliance with the National Institutes of Health guidelines (NIH publication No. 85–23, revised 2011) and in accordance with the Ethics Committee of the National Research Centre, Egypt (registration number 18/127).

2.2. Drugs and chemicals

Adrenaline 1 mg/ml S.C. ampoules (Cid, Giza, Egypt) (commercially available, CID, Egypt). Thymol was purchased from Sigma-Aldrich (St Louis, MO, USA).

2.3. Experimental design

Rats were randomly allocated into 5 groups (8 rats/per group). Group I: received distilled water orally for 21 consecutive days. On day 22, distilled water was administered subcutaneously as a single dose for 2 consecutive days (24 h apart) (served as normal). Groups II: received distilled water orally for 21 consecutive days. On day 22, adrenaline (2 mg/kg, s.c.) was injected as a single dose for 2 consecutive days (24 h apart) (served as control MI). Groups (III–V): received Thymol (15, 30, 60 mg/kg, p.o.), respectively for 21 consecutive days. On day 22, adrenaline (2 mg/kg, s.c.) was injected as a single dose for 2 consecutive days (24 h apart). The doses of adrenaline and thymol were selected according to previous published data of Amin et al. (2016) and Asadbegi et al. (2018), respectively.

2.4. ECG examination

Rats were anesthetized with thiopental (45 mg/kg, i.p.). ECG was recorded for 1 min by inserting subcutaneous peripheral limb electrodes using ECG Powerlab module that consists of Powerlab/8sp, and animal bio-amplifier, Australia, in addition to Lab Chart7 software with ECG analyzer (Salama et al., 2018). Heart rate (HR), RR interval, and ST height were recorded.

2.5. Serum collection and tissue preparation

Blood samples were collected from the retro-orbital sinus of rats. Collected blood samples were centrifuged using a cooling centrifuge (2k15; Sigma/Laborzentrifugen) at 1538g for 10 min and the resulting serum was used for determining AST, LDH, and CK levels.

Rats were sacrificed after 24 h of adrenaline administration under light anesthesia with ether. Hearts were isolated and homogenized (MPW-120; Medical Instruments) in 20% (w/v) ice-cold phosphate buffer. Then, the homogenate was centrifuged using a cooling centrifuge (2k15; Sigma/Laborzentrifugen) at 1538g for 5 min and the resulting supernatant was used for determining the cardiac contents of malondialdehyde (MDA), reduced glutathione (GSH), nuclear factor kappa B (NF-κB), and interleukin-1beta (IL-1β).

2.6. Serum biochemical parameters

2.6.1. Serum AST level

Serum AST was measured using Reitman and Frankel (1957) method. The concentration was measured spectrophotometrically at 505 nm. The serum AST level is expressed as U/L.

2.6.2. Serum LDH level

LDH level was estimated using the enzymatic method according to manufacturer instructions (ChronoLab, France) and measured spectrophotometrically at 340nm. Serum LDH level is expressed as U/L.

2.6.3. Serum CK level

CK level was determined enzymatically using Abbot et al. (1984) method and the concentration was measured using spectrophotometer at 340 nm. Serum CK level is expressed as U/L.

2.7. Cardiac biochemical parameters

2.7.1. Determination of cardiac MDA content

Lipid peroxidation was assayed by measuring cardiac levels of MDA according to the method described by Ruiz-Larrea et al. (1994). The supernatant was read spectrophotometrically at 532 nm, and the cardiac content is expressed in nanomoles of MDA per milligram of cardiac tissue.

2.7.2. Determination of cardiac GSH content

Cardiac GSH content was determined according to the method described by Ellman (1959). Calculation of GSH concentration was based on a standard GSH curve and is expressed in micromoles of GSH per gram of cardiac tissue.

2.7.3. Determination of cardiac NF-κB content

NF-κB content was determined using a rat-specific immunoassay kit (Rat NF-κB ELISA) from Biosource, Inc., according to the manufacturer's protocol. The intensity of the colored product was directly proportional to the concentration of rat NF-κB, as determined by microplate reader (Biotek ELx800) set at 450 nm. The sample concentration was determined against a standard curve and is expressed in nanogram of NF-κB per gram of cardiac tissue.
2.7.4. Determination of cardiac IL-1β content

IL-1β content was determined using a rat-specific immunoassay kit (Rat IL-1β ELISA) from Glory Science (Del Rio, Texas, USA), according to the manufacturer’s protocol. The intensity of the colored product was directly proportional to the concentration of rat IL-1β, as determined by microplate reader (Biotech ELX800) set at 450 nm. The sample concentration was determined against a standard curve and is expressed in nanogram of IL-1β per gram of cardiac tissue.

2.8. Histopathological examination

Different sections from the normal and treated hearts were removed and fixed in 10% neutral formalin for 48h. The tissues were washed, dehydrated and embedded in paraffin. Finally, 4 μm thick sections were stained with H&E for assessment of the histopathological lesions including cardiomyocyte necrosis and leukocytic infiltration. Ten sections per group were examined. The lesions were semi quantitatively graded according to the method of Downing and Lee (1983). Score 0 = no histological abnormality, 0.5 = the lesions are focal and equivocal, 1 = the lesions are definite and scarce, 1.5 = the lesions are extensive and non-transmural and 2 = the lesions are extensive and transmural.

2.9. Immunohistochemical analysis

Immunohistochemical staining of activated caspase-3 and Bcl-2 was performed as previously described (Ibrahim et al., 2015). The heart sections were deparaffinized, rehydrated and blocked in 3% hydrogen peroxide. Then, the sections were incubated with rabbit polyclonal anti-caspase-3 (1:1000 dilution; BD Biosciences, Le Pont-de-Claix, France) and mouse monoclonal anti-Bcl-2 (1:200 dilution, Santa Cruz Biotechnology) as primary antibodies. Diaminobenzidine (DAB) chromogen was added to visualize the immune reaction. Finally, the slides were counterstained in hematoxylin and cover-slipped. Semi quantitative grading score for assessment of activated caspase-3 and Bcl-2 was carried out, in ten random high power fields, according to the percentage of immune stained cells in high power field (HPF) (40x). Score 0 = no staining; 1-positive staining in < 25% of cells/HPF; 2-positive staining in 25–50% of cells/HPF; 3-positive staining in >50% of cells/HPF.

2.10. Statistical analysis

Data are expressed as mean ± SEM. Comparison for more than 2 groups were carried out by one way ANOVA followed by Tukey’s multiple comparison test, except for histopathological and immunohisto pathological analyses were carried out by one way ANOVA followed by Newman-Keuls multiple comparisons test. All analyses utilized GraphPad Prism 6.0 statistical package for Windows (GraphPad, San Diego, Calif.). Statistical significance was set at p < 0.05.

3. Results

3.1. Effect of thymol on HR, RR, and ST interval of adrenaline-induced MI in rats

Table 1 shows that MI-induced by single s.c. injection of adrenaline in a dose of 2 mg/kg for 2 successive days showed a significant decrease in HR by 30.69%, increase in RR interval by 60.36% and increase in ST interval by 561.54%, as compared to normal rats.

Oral pretreatment of thymol in doses of 15, 30, and 60 mg/kg showed a significant increase in HR by 57.37, 35.98, and 32.94%, respectively decrease in RR interval by 30.63, 30.26 and 26.20%, respectively, and decrease in ST interval by 32.94, 26.20, and 76.74%, respectively as compared to control (MI) rats.

3.2. Effect of thymol on serum biochemical parameters

As depicted in Table 2, adrenaline-induced MI resulted in significant increase in serum AST, LDH, and CK levels by 50.96, 71.31, and 59.96%, respectively as compared to normal rats.

Oral pretreatment of thymol (15 mg/kg) showed a significant decrease in AST level by 16.32% as compared to control (MI) group and was significant from normal group. Thymol treatment (30, 60 mg/kg) significantly reduced AST level by 24.00, and 36.24%, respectively as compared to control (MI) group.

Oral administration of thymol (15 mg/kg) tended to decrease LDH level but this decrease was not significant from control (MI) group. Thymol (30 mg/kg) still showed a significant increase in LDH level to be similar to control (MI) group. At a dose of 60 mg/kg, thymol significantly reduced LDH level by 31.29% as compared to control (MI) rats.

Regarding CK level, Thymol (15 mg/kg) significantly decreased CK level by 27.63% when compared to control (MI) group and increased it by 15.77% as compared to normal group. Oral pretreatment with thymol (30 mg/kg) significantly reduced CK level by 30.35% as compared to normal group at p < 0.05.

Table 1. Effect of Thymol on ECG pattern.

| Parameters          | Treatment              | Heart rate (bpm) | RR interval (s) | ST segment |
|---------------------|------------------------|------------------|----------------|------------|
| Normal              | 356.100±6.727         | 0.169±0.002      | 0.013±0.003    |
| Control (MI)        | 246.800±15.990        | 0.271±0.033      | 0.086±0.016    |
| Thymol (15 mg/kg)   | 388.400±7.952         | 0.188±0.007      | 0.043±0.009    |
| Thymol (30 mg/kg)   | 335.600±33.980        | 0.198±0.018      | 0.040±0.010    |
| Thymol (60 mg/kg)   | 328.100±6.171         | 0.200±0.013      | 0.020±0.000    |

Data are presented as mean ± SEM. Statistical analysis are carried by one way ANOVA followed by Tukey’s multiple comparison test.

*Significant difference from normal group at p < 0.05.

Table 2. Effect of Thymol on serum biochemical parameters.

| Parameters          | Treatment | AST (U/L) | CK (U/L) | LDH (U/L) |
|---------------------|-----------|-----------|----------|-----------|
| Normal              | 414.900±10.377 | 110.51±2.091 | 450.64±26.35 |
| Control (MI)        | 626.33±20.164    | 176.77±3.383   | 771.99±17.53 |
| Thymol (15 mg/kg)   | 524.10±11.492    | 127.937±0.086  | 549.14±49.45 |
| Thymol (30 mg/kg)   | 476.000±16.326   | 123.122±2.768  | 795.39±48.46 |
| Thymol (60 mg/kg)   | 399.333±17.740   | 147.196±0.691  | 530.42±94.77 |

Data are expressed as mean ± SEM. Statistical analysis are carried by one way ANOVA followed by Tukey’s multiple comparison test.

*Significant difference from normal group at p < 0.05.

Table 3. Effect of thymol on MDA and GSH contents in heart homogenate.

| Parameters          | Treatment | MDA (nmol/mg) | GSH (μmol/g) |
|---------------------|-----------|---------------|--------------|
| Normal              | 174.038±4.591 | 3.937±0.104   |
| Control (MI)        | 390.064±22.482 | 2.573±0.057   |
| Thymol (15 mg/kg)   | 178.098±13.818 | 3.622±0.312   |
| Thymol (30 mg/kg)   | 160.381±7.239  | 4.534±0.166   |
| Thymol (60 mg/kg)   | 178.893±0.779  | 3.916±0.161   |

Data are expressed as mean ± SEM. Statistical analysis are carried by one way ANOVA followed by Tukey’s multiple comparison test.

*Significant difference from normal group at p < 0.05.

*Significant difference from control (MI) group at p < 0.05.
control rats. Thymol (60 mg/kg) resulted in significant decrease in CK level by 16.73% as compared to control rats and was significantly different from normal value.

3.3. Effect of thymol on cardiac oxidative stress biomarkers

As demonstrated in Table 3, adrenaline-induced MI showed a significant elevation in MDA cardiac content by 124.13% as compared to normal rats. Oral pretreatment with thymol (15, 30, and 60 mg/kg) significantly reduced cardiac MDA content by 54.34, 56.58, and 54.14%, respectively as compared to control rats.

Control (MI) rats resulted in significant reduction of cardiac GSH content by 34.65% as compared to normal rats. Thymol (15, 30, and 60 mg/kg) significantly restored cardiac GSH content by 40.77, 76.21, and 52.20%, respectively as compared to control rats (Table 3).

3.4. Effect of thymol on cardiac inflammatory mediators

Table 4 illustrates that cardiac contents of NF-κB, and IL-1β in control MI rats were significantly increased by 372.18, and 7.92%, respectively as compared to normal rats.

Significant decrease in cardiac NF-κB content was depicted after thymol pretreatment (15, 30, 60 mg/kg) in MI rats in a dose dependent manner by 42.78, 60.785, and 72.41%, respectively as compared to control rats.

Thymol (15, 30, 60 mg/kg) significantly reduced IL-1β cardiac content by 5.34, 6.20, and 6.73%, respectively as compared to control rats.

3.5. Histopathology

Heart of normal rats revealed normal cardiac muscle fibers with no definite lesions (cardiomyocytes necrosis and inflammation) (mean score, 0.00/0.00) (Figure 1a). Conversely, severe MI involving the full thickness of the heart tissue was demonstrated in control (MI) group (mean score, 1.90/0.06). Abundant contraction bands of necrotic cardiomyocytes with fragmentation of myofibers were frequently demonstrated in this group. The necrotic cardiomyocytes are intensely eosinophilic and diffusely

![Photomicrograph of heart tissue stained with H&E. (a) Normal rats showing normal cardiomyocytes, (b) Control (MI) group showing contraction bands of necrotic cardiomyocytes which are diffusely infiltrated with massive cellular infiltrates, (c) Thymol (15 mg/kg) group showing focal necrosis of cardiomyocytes that are infiltrated with mononuclear cells, (d) Thymol (30 mg/kg) showing minute focal aggregation of histiocytes, and (e) Thymol (60 mg/kg) showing normal cardiomyocytes, (f) The mean pathological score recorded in the heart tissue of all groups (H&E, 40X). The data are presented as mean ± SEM. Statistical analysis was carried out by one-way ANOVA followed by Newman-Keuls multiple comparison test.*Significant difference from normal group at p < 0.05. @Significant difference from control (MI) group at p < 0.05.](image-url)
infiltrated with massive cellular infiltrates (Figure 1b). The cellular infiltrates are mostly mononuclear cells and large histiocytes. Apoptotic cardiomyocyte with condensed chromatin was also observed. Mild attenuation of the lesions was demonstrated in thymol (15 mg/kg) (mean score, 1.70 ± 0.11) in which focal necrosis of cardiomyocytes was evident (Figure 1c). Marked regression of cardiomyocyte necrosis and inflammatory cellular infiltrates were recorded in thymol (30 mg/kg) (Figure 1d) (mean score, 1.40 ± 0.14). Remarkable amelioration was noticed in thymol (60 mg/kg) with normal cardiomyocytes in most examined sections (Figure 1e) (mean score, 0.60 ± 0.12).

3.6. Immunohistochemistry

The results of immunohistochemical analysis recorded in normal and treated hearts were illustrated in Figures 2 & 3.

3.6.1. Activated caspase-3 protein expression

No caspase-3 expression was demonstrated in normal heart (Figure 2a). While, control (MI) group revealed significant increase of caspase-3 expression that was demonstrated in the cardiomyocyte sarcoplasm and apoptotic nuclei as well as the endothelial lining of the blood vessels (Figure 2b). Additionally, the inflammatory cells surrounding the necrotic muscle fibers showed intense immune staining. Decreased expression of activated caspase-3 was recorded in thymol (15 mg/kg) pretreated group. The immune reaction was demonstrated in the endothelial lining of the blood vessels and few cardiomyocytes (Figure 2c). Significant decrease of activated caspase-3 was recorded in thymol 15, 30 and 60 mg/kg pretreated groups that was demonstrated in the cytoplasm of sparse cardiomyocytes (Figure 2d & e, respectively).

3.6.2. Bcl-2 protein expression

Bcl-2 protein expression was non-detectable in normal heart (Figure 3a). In control (MI) group, Bcl-2 protein expression was demonstrated in the necrotic area that are infiltrated by inflammatory cells, but few sparse cardiomyocytes exhibiting Bcl-2 protein immune reactivity were demonstrated in other areas (Figure 3b). Non-significant difference in Bcl-2 protein expression was recorded in thymol (15 mg/kg) pretreated group, which revealed weak expression (Figure 3c). While, significant increase in Bcl-2 protein expression was recorded in thymol 30 and 60 mg/kg pretreated groups respectively (Figure 3d & e, respectively).

4. Discussion

This study provides new evidence on the cardioprotective effect of thymol (15, 30, 60 mg/kg) against adrenaline-induced MI in rats. To the best of the authors’ knowledge this is considered the first study to investigate the role of cardiac enzymes, ECG alterations, oxidative stress, inflammation, apoptosis as well as histopathological changes of thymol in adrenaline-induced MI in rats.

Subcutaneous administration of adrenaline (2 mg/kg) for 2 consecutive days in the present study resulted in abnormalities in ECG pattern...
as manifested by prolongation of RR interval, decrease in HR, and elevation in ST interval. This finding is in harmony with that of Salama et al. (2018) and indicates the induction of myocardial damage by adrenaline. Adrenaline associated prolongation of RR interval may be due to atrioventricular block (Nakamura et al., 2006) and ST segment elevation which is a sign of acute myocardial infarction (Khodeer et al., 2019).

In the current study, adrenaline administration elevated serum levels of cardiac enzymes; AST, LDH, and CK levels as described earlier (Wang et al., 2017). This reveals that adrenaline administration lead to myocardial damage and leakage of cardiac enzymes into the circulation.

Thymol pretreatment reduced the elevated RR and ST intervals and controlled HR, implicating amelioration in ECG pattern. Thymol administration reduced serum levels of AST, CK and LDH, reflecting preservation of membrane integrity and thereby cardioprotection against adrenaline-induced MI. Those findings are paralleled by improved histopathological features of cardiac lesions and are in consistency with a prior study of El-Sayed et al. (2016) who demonstrated the cardioprotective effects of thymol against doxorubicin-induced cardiotoxicity.

The cardiac cells contain a huge number of mitochondria which is the primary source of energy and ROS in mammalian cells (Dhalla et al., 1993; Marchi et al., 2012). Adrenaline administration elevated MDA (marker of lipid peroxidation) and reduced GSH (endogenous anti-oxidant) cardiac contents in rats. This finding is in accordance to prior study of Mishra et al., 2016) and implicates that oxidative stress mediated adrenaline-induced MI and disruption of myocardial membrane.

Thymol pretreatment significantly restored cardiac MDA and GSH contents in rats. This reveals that thymol exerted its cardioprotective effect against adrenaline-induced MI through its anti-oxidant activity. This finding is in line with prior study of Meeran and Prince (2012).

Oxidative stress leads to cell inflammation (Wood, 2020). ROS activates NF-κB, a central player that regulates the development of inflammatory cardiac vascular damage via elevating inflammatory cytokines (e.g. TNF-α, IL-1β) (Gloire et al., 2006; Fiordelisi et al., 2019). In line with this notice, adrenaline significantly elevated cardiac NFκB and IL-1β contents, demonstrating that inflammation mediated adrenaline-induced MI in rats.

In this work, NF-κB and IL-1β were suppressed by thymol pretreatment, indicating that thymol exerted its cardioprotective effect against adrenaline-induced MI via its anti-inflammatory effect mediated by its anti-oxidant effect. This was paralleled with improved cardiac function indices and further confirmed previous reports that showed the importance of inhibition of inflammatory cytokines in alleviation of cardiac injury (Seropian et al., 2014; Raish et al., 2019). The anti-inflammatory effect of thymol was described also in acute lung injury model via inhibition of TNF-α, IL-6 releases and NF-κB activation (Wan et al., 2018).
Oxidative stress is closely associated with cell apoptosis (Yu et al., 2015). Excessive ROS production leads to oxidative stress accompanied with intracellular macromolecules (DNA, proteins, membrane lipids) damage, thus, killing the cells either by apoptosis or necrosis (Zaki et al., 2018). In response to injurious stimuli, NF-κB is translocated to the nucleus, phosphorylated and binds to target genes including TNF-α, interleukins (e.g IL-1β and IL-6), and anti-apoptotic proteins such as Bcl2 (Maimaitiali et al., 2018).

Persistent MI is accompanied with apoptosis and progressive loss of cells with subsequent cardiac remodeling, ventricular dilation, myocardial fibrosis, gradual decrease of cardiac function and heart failure after progression of myocardial infarction (Konstantinova et al., 2011; Rondeau et al., 2011). Bcl-2 expression blocks features of apoptosis, like plasma membrane blebbing, DNA cleavage, and nuclear condensation. Thus, it plays a crucial role in cell survival and acts as a negative regulator of cell death induced by various stimuli. Caspase-3 is a key mediator of apoptosis that catalyzes the cleavage of key cellular proteins having a role in the crosstalk between inflammation and apoptosis (Porter and Janicke, 1999).

Additionally, myocardial apoptosis speeds up the development of necrosis the effect that determines the degree of MI. This was observed in the current study through histopathological examination which showed both apoptotic and necrotic cardiomyocytes upon adrenaline injection. Bcl-2 (B cell lymphoma 2), a proto-oncogene that is associated with apoptosis. It is an anti-apoptotic gene and a key downstream target gene of NF-κB (Ola et al., 2011) that is subsequently activated to regulate inflammatory responses, cell differentiation and apoptosis. In the same manner, adrenaline administration significantly reduced Bcl2 protein expression and elevated caspase-3 protein expression as compared to normal rats, showing that adrenaline-induced MI was mediated by apoptosis. This finding is inaccordance with that of Salama et al. (2018).

Thymol pre-treatment in the present work resulted in increased protein expression of Bcl2 and suppression of caspase-3 with marked regression of apoptosis and necrosis, revealing that its anti-inflammatory and anti-apoptotic effect mediated its anti-apoptotic and thereby cardioprotective effect against adrenaline-induced MI. Similarly, thymol showed previous anti-apoptotic effect in carotid tissue of hypercholesterolemic rats (Baymatkoo et al., 2017).

5. Conclusion

It can be concluded that thymol possessed cardioprotective effect against adrenaline-induced MI in rats possibly by ameliorating cardiac tissue biomarkers, attenuating ECG changes, improving histopathological changes resulting from oxidative stress, inflammation and apoptosis. More studies are warranted to study the exact molecular mechanisms that may play a role in the cardioprotective effect of thymol in MI rats.

Declarations

Author contribution statement

S.A. El-Marasy, S.A. El Awdan and H.M.I. Abdallah: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

A. Hassan: Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

- Abbot, B., Young, D.S., Burris, A., 1984. Creatine kinase. In: Kaplan, A. (Ed.), Clinical Chemistry, edn. The C.V. Mosby Co., St Louis, Toronto, Princeton, pp. 1112–1116.
- Alam, K., Nagi, M.N., Badary, O.A., Al-Shabanah, O.A., Al-Khaili, A.C., Al-Beikawi, A.M., 1999. The protective action of thymol against carbon tetrachloride hepatotoxicity in mice. Pharmacol. Res. 40 (2), 159–163.
- Amin, M.M., El Gazarleyy, O.N., Abd El-Gawad, N.A., Abd El-Halim, S.M., El-Awdan, S.A., 2016. Effect of formulation variables on design, in vitro evaluation of valsartan SNEDDS and estimation of its antioxidant effect in adrenaline-induced acute myocardial infarction in rats. Pharmaceut. Dev. Technol. 21 (8), 909–920.
- Andreaudou, I., Ibirodmitmis, E.K., Farmakis, D., Kremastinos, D.T., 2009. To prevent, protect and save the ischemic heart: antioxidants revisited. Expert Opin. Ther. Targets 13 (8), 945–956.
- Asadbegi, M., Komaki, A., Salehi, I., Yaghmaei, P., EBrahim-Habibi, A., Shahidi, S., Sarlhi, A., Soleimani Ad, S., Golpoor, Z., 2018. Effects of thymol on amyloid-beta-induced impairments in hippocampal synaptic plasticity in rats fed a high-fat diet. Brain Res. Bull. 137, 338–350.
- Attalalla, D.M., Ahmed, I.A., Zaki, H.F., Khabat, M.M., 2018. Paradoxical effects of atorvastatin in isoproteinol-induced cardiotoxicity in rats: role of oxidative stress and inflammation. Biomed. Pharmacother. 104, 542–549.
- Aydin, S., Ugur, K., Aydin, S., Sahin, I., Yardim, M., 2019. Bionarkers in acute myocardial infarction: current perspectives. Vasc. Health Risk Manag. 15, 1–10.
- Baymatkoo, R., Rashitcheizadeh, N., Yaghmaei, P., Farsioubi, M., Karimi, P., 2017. Thymol decreases apoptosis and inflammation induced by hypercholesterolemia through a discount in oxidative stress. Crescent J. of Med. and Biolog. Sci. 4 (4), 186–193.
- Bei, W., Jing, L., Chen, N., 2020. Cardio protective role of wogonin loaded nanoparticle against isoproteinol induced myocardial infarction by moderating oxidative stress and inflammation. Colloids Surf. B Biointerfaces 185, 110635.
- Capo, X., Martorell, M., Busquets-Cortes, C., Tejada, S., Tur, J.A., Pons, A., Surelza, A., 2018. Resulvins as proresolving inflammatory mediators in cardiovascular disease. Eur. J. Med. Chem. 153, 123–130.
- Cerretani, D., Fineschi, V., Bello, S., Riezzo, I., Turillazzi, E., Nerli, M., 2012. Role of oxidative stress in cocaine-induced cardiotoxicity and cocaine-related death. Curr. Med. Chem. 19 (33), 5619–5623.
- Dhalln, N.S., Afzal, N., Beammsh, R.E., Naimark, B., Takeda, N., Nagano, M., 1993. Pathophysiology of cardiac dysfunction in congestive heart failure. Can. J. Cardiol. 9 (10), 873–887.
- Diaz-Cruz, A., Guinzberg, R., Guerra, R., Vilchis, M., Carrasco, D., Garcia-Vazquez, F.J., Pina, E., 2007. Adrenaline stimulates H2O2 generation in liver via NADPH oxidase. Free Radic. Res. 41 (6), 663–672.
- Downing, S.E., Lee, J.C., 1983. Contribution of alpha-adrenoceptor activation to the pathogenesis of norepinephrine cardiomyopathy. Circ. Res. 52 (4), 471–478.
- El-Sayed, E.S.M., Mansour, A.M., Abdul-Hameed, M.S., 2016. Thymol and carvacrol anti-inflammatory effect mediated its anti-apoptotic and thereby caridoprotective effect against adrenaline-induced MI. Similarly, thymol showed previous anti-apoptotic effect in carotid tissue of hypercholesterolemic rats (Baymatkoo et al., 2017).
- Fiordelisi, A., Iaccarino, G., Morisco, C., Coscioni, E., Sorriento, D., 2019. NFκB is a key player in the crosstalk between inflammation and cardiovascular diseases. Int. J. Mol. Sci. 20 (7).
- Goldberg, G., Legrand-Poels, S., Piette, J., 2006. NFκB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 72 (11), 1493–1505.
- Hara, M.R., Koves, J.J., Whalen, E.J., Rajagopal, S., Strachan, R.T., Grant, W., Towers, A.J., Williams, B., Lenn, C.M., Xiao, K., Shenoy, S.K., Gregory, S.G., Ahn, S., Duckett, D.B., Lerkowitz, R.J., 2011. A stress response pathway regulates DNA damage through beta2-adrenoceptors and beta-arrestin-1. Nature 477 (7364), 349–353.
- Ibrahim, M.A., Khalaf, A.A., Galal, M.K., Ogaly, H.A., M., H., A.H., 2015. Ameliorative influence of green tea extract on copper nanoparticle-induced hepatotoxicity in rats. Nanoscale Res Lett 10 (1), 363.
- Kodher, D.M., Bilasy, S.E., Farag, N.E., Mehana, A.E., Elbaz, A.A., 2019. Sitagliptin protects diabetic rats with acute myocardial infarction through induction of angiogenic role of IFG-1 and VEGF. Can. J. Physiol. Pharmacol. 97 (11), 1053–1063.
- Konstantinova, E.V., Khomyakova, N.F., Konstantinova, N.A., Podkolzin, A.V., Saposhnikov, A.M., 2011. Relationship between apoptosis and expression of heat shock proteins in peripheral blood lymphocytes of patients with myocardial infarction. Bull. Exp. Biol. Med. 150 (6), 682–684.
- Li, H., Xie, Y.H., Yang, Q., Wang, S.W., Zhang, B.L., Wang, J.B., Cao, W., Bi, L.L., Sun, J.Y., Miao, S., Hu, J., Zhou, X.X., Qiu, P.C., 2012. Cardioprotective effect of paeonol and thymol.
